Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.
Beyer I, Cao H, Persson J, Wang H, Liu Y, Yumul R, Li Z, Woodle D, Manger R, Gough M, Rocha D, Bogue J, Baldessari A, Berenson R, Carter D, Lieber A.
Beyer I, et al. Among authors: gough m.
Mol Ther. 2013 Feb;21(2):291-9. doi: 10.1038/mt.2012.212. Epub 2012 Oct 23.
Mol Ther. 2013.
PMID: 23089733
Free PMC article.